Prostate Cancer Daily

June 01, 2026

Videos

Peer-to-Peer Clinical Conversations

Radiopharmaceuticals in Prostate Cancer Part 1: Current Landscape and Unmet Needs - Dustin Boothe & Praful Ravi

Praful Ravi

Praful Ravi and Dustin Boothe discuss the clinical positioning of lutetium-177 PSMA in metastatic CRPC with Philip Kantoff, working through patient selection, sequencing, and progression after Pluvicto.

View

Integrating Genomic Prognostic and Hallmark Signatures to Predict Outcomes in Active Surveillance - Kevin Shee

Kevin Shee

Kevin Shee analyzes Decipher® GRID whole-transcriptome data in 500 active surveillance patients from UCSF.

View

Beyond the Abstracts

A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care - Beyond the Abstract

Real-World Burden and Management of Late Genitourinary Toxicity after Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation - Beyond the Abstract

Conference Coverage

ASCO 2026: REINFORCE: A Phase III Randomized Trial of Treatment Intensification with Docetaxel in mHSPC Patients Without Deep PSA Response After Initial Apalutamide Therapy Acetate

ASCO 2026: Classification Tree Phenotypes for Early Treatment-Limiting Toxicity After ARPI Initiation in mHSPC from the IRONMAN Registry

ASCO 2026: Real-World Use of Olaparib in US Veterans with mCRPC: Treatment Patterns and Outcomes

ASCO 2026: Quantitative Results from PSMAtrack: A Prospective Study Evaluating Change in PSMA-PET During Initial Systemic Therapy for mHSPC

ASCO 2026: Independent Validation of a Model to Predict Early Favorable PSA Response (NADIR Model) in Enzalutamide-Treated Patients of the ARCHES Trial

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Top advances of the year: Radiopharmaceutical therapy for prostate cancer.

Success and Limitations of PSMA RLT : The Nuclear Medicine View.

ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes.

Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk.

Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study.

Serum micronutrient levels in men with prostate carcinoma: An observational study at a tertiary care health facility.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login